A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Epigenetic events and genetic alterations under the control of the tumor microenvironment potentially mediate tumor induced angiogenesis involved in soft tissue sarcoma (STS) metastasis. Addition of antiangiogenic agent, such as bevacizumab, to standard chemotherapy in treatment of sarcoma has been...

Full description

Bibliographic Details
Main Authors: Varun Monga, Umang Swami, Munir Tanas, Aaron Bossler, Sarah L. Mott, Brian J. Smith, Mohammed Milhem
Format: Article
Language:English
Published: MDPI AG 2018-02-01
Series:Cancers
Subjects:
sarcoma
valproic acid
rheostat
angiogenesis
epigenetics
bevacizumab
Online Access:http://www.mdpi.com/2072-6694/10/2/53

Similar Items

Similar Items